Literature DB >> 11317000

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.

H Chakraborty1, P K Sen, R W Helms, P L Vernazza, S A Fiscus, J J Eron, B K Patterson, R W Coombs, J N Krieger, M S Cohen.   

Abstract

OBJECTIVE: To develop a model to predict transmission of HIV-1 from men to women.
DESIGN: HIV-1 in seminal plasma, and endocervical CCR5 receptors were correlated with epidemiological studies of HIV-1 transmission to develop a probabilistic model. SETTINGS: Semen samples were collected from patient subjects in Seattle Washington, Chapel Hill, North Carolina, and St. Gallen, Switzerland. Endocervical biopsy specimens were obtained from women in Chicago, Illinois. PARTICIPANTS: Eighty-six men (not receiving antiretroviral therapy) in whom CD4 cell count and semen volume were available, and 24 women in whom the number of endocervical CCR5 receptors were determined. MAIN OUTCOME MEASURES: Prediction of transmission of HIV-1 from men to women per episode of vaginal intercourse based on the absolute burden of HIV (volume x HIV RNA copies/ml seminal plasma).
RESULTS: The model suggests efficient heterosexual transmission of HIV-1 when semen viral burden is high. When semen contains 100 000 copies of non-syncytium-inducing (NSI) HIV RNA the probability of HIV-1 transmission is 1 per 100 episodes of intercourse; conversely, with 1000 copies NSI HIV RNA in semen, transmission probability is 3 per 10 000 episodes of intercourse.
CONCLUSIONS: This model links biological and epidemiological data related to heterosexual HIV-1 transmission. The model can be used to estimate transmission of HIV from men with high semen viral burden from inflammation, or reduced burden after antiretroviral therapy. The results offer a biological explanation for the magnitude of the HIV epidemic in places where earlier studies have shown men have high semen viral burden, such as in sub-Saharan Africa. The model can be used to develop and test HIV-1 prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317000     DOI: 10.1097/00002030-200103300-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  105 in total

1.  Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota.

Authors:  Caroline Mitchell; Jane Hitti; Kathleen Paul; Kathy Agnew; Susan E Cohn; Amneris E Luque; Robert Coombs
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Authors:  Meredith R Clark; Hyder A Aliyar; Chang-won Lee; Julie I Jay; Kavita M Gupta; Karen M Watson; Russell J Stewart; Robert W Buckheit; Patrick F Kiser
Journal:  Int J Pharm       Date:  2011-04-12       Impact factor: 5.875

Review 3.  Use of assisted reproductive technology to reduce the risk of transmission of HIV in discordant couples wishing to have their own children where the male partner is seropositive with an undetectable viral load.

Authors:  H W G Baker; A Mijch; S Garland; S Crowe; M Dunne; D Edgar; G Clarke; P Foster; J Blood
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

Review 4.  HIV/AIDS prevention in Latino and African-American communities.

Authors:  Claudia Medina; William Johnson
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

5.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

6.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

7.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Authors:  Theresa L-Y Chang; Chia-Hwa Chang; David A Simpson; Qiang Xu; Patrick K Martin; Laurel A Lagenaur; Gary K Schoolnik; David D Ho; Sharon L Hillier; Mark Holodniy; John A Lewicki; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

8.  Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.

Authors:  James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model.

Authors:  Kathleen J Sikkema; Melissa H Watt; Anya S Drabkin; Christina S Meade; Nathan B Hansen; Brian W Pence
Journal:  AIDS Behav       Date:  2010-04

Review 10.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.